Vanguard Capital Management’s Apimeds Pharmaceuticals US APUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.8K Sell
5,162
-1,203
-19% -$5.82K ﹤0.01% 3961
2026
Q2
$57.3K Sell
6,365
-3,228
-34% -$44K ﹤0.01% 3926
2026
Q1
$172K Buy
+9,593
New +$154K ﹤0.01% 3816

Other funds holding APUS

Vanguard Capital Management's APUS Position: Q3 2026 in Review

Vanguard Capital Management reduced its Apimeds Pharmaceuticals US (APUS) stake by 19% in Q3 2026, selling an estimated $5.82K and leaving 5,162 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3961.

Vanguard Capital Management first reported a position in APUS in Q1 2026 and has held it in 3 quarters since. The position peaked at $172K in Q1 2026. 9 funds tracked by Wall St. Rank hold APUS as of Q3 2026.

  • Vanguard Capital Management held 5,162 shares of Apimeds Pharmaceuticals US worth $25.8K as of Q3 2026.
  • Vanguard Capital Management sold 1,203 Apimeds Pharmaceuticals US shares in Q3 2026, an estimated $5.82K.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3961 holding.
  • Vanguard Capital Management first reported a position in Apimeds Pharmaceuticals US in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Apimeds Pharmaceuticals US position peaked at $172K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.